- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2019
- Public Summary Document (PSD) March 2019 PBAC Meeting - PDF
- Public Summary Document (PSD) March 2019 PBAC Meeting - Word
Ocriplasmin – March 2019
Ocriplasmin: Solution for intravitreal injection 0.375 mg in 0.3 mL; Jetrea® RTU
Last updated
5 July 2019
